This company is no longer active
InDex Pharmaceuticals Holding Management
Management criteria checks 2/4
InDex Pharmaceuticals Holding's CEO is Jenny Sundqvist, appointed in Jan 2023, has a tenure of 1.42 years. total yearly compensation is SEK3.54M, comprised of 64% salary and 36% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth SEK65.60K. The average tenure of the management team and the board of directors is 4.6 years and 8.4 years respectively.
Key information
Jenny Sundqvist
Chief executive officer
SEK 3.5m
Total compensation
| CEO salary percentage | 64.0% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.6yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -SEK 56m |
| Dec 31 2023 | SEK 4m | SEK 2m | -SEK 95m |
Compensation vs Market: Jenny's total compensation ($USD338.03K) is above average for companies of similar size in the Swedish market ($USD256.68K).
Compensation vs Earnings: Insufficient data to compare Jenny's compensation with company performance.
CEO
Jenny Sundqvist (53 yo)
1.4yrs
Tenure
SEK 3,543,000
Compensation
Ms. Jenny Sundqvist serves as Chief Executive Officer of InDex Pharmaceuticals Holding AB (publ) since January 01, 2023. She served as Chief Commercial Officer of Isofol Medical AB (publ) from January 1, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.4yrs | SEK 3.54m | 0.023% SEK 65.6k | |
| Deputy CEO & Chief Financial Officer | 7.1yrs | SEK 2.80m | 0.073% SEK 209.8k | |
| Chief Scientific Officer | 2.1yrs | no data | 0.0017% SEK 4.9k | |
| Head of Regulatory Affairs | 11.4yrs | no data | no data |
4.6yrs
Average Tenure
56yo
Average Age
Experienced Management: INDEX's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 13.4yrs | SEK 235.00k | 0.081% SEK 232.4k | |
| Independent Director | 8.4yrs | SEK 235.00k | 0.077% SEK 219.5k | |
| Director | less than a year | no data | no data | |
| Member of Advisory Board - North America | no data | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Independent Chairman | 13.4yrs | SEK 500.00k | 0.14% SEK 406.6k | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Chairman of Advisory Board - Europe | 2yrs | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Member of Advisory Board - North America | no data | no data | no data |
8.4yrs
Average Tenure
70yo
Average Age
Experienced Board: INDEX's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/10 11:12 |
| End of Day Share Price | 2024/06/10 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InDex Pharmaceuticals Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvid Necander | Carnegie Investment Bank AB |
| Filip Einarsson | Redeye |